The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.
Stewart
A
A
West Midlands Development and Evaluation Service, The University of Birmingham, Birmingham, UK.
Sandercock
J
J
Bryan
S
S
Hyde
C
C
Barton
P M
PM
Fry-Smith
A
A
Burls
A
A
D003362:Cost-Benefit Analysis; D006801:Humans; D015994:Incidence; D016472:Motor Neuron Disease / Q000188:drug therapy* / Q000453:epidemiology; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D015995:Prevalence; D016032:Randomized Controlled Trials as Topic; D019782:Riluzole / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
D018696:Neuroprotective Agents; D019782:Riluzole